研究者詳細

顔写真

イカリ　トモオ
猪狩　智生
Tomoo Ikari
所属
大学院医学系研究科　医科学専攻　外科病態学講座（緩和医療学分野）
職名
助教
学位

  • 博士（医学） （北海道大学）

e-Rad 研究者番号
90962845

経歴 9

  • 2023年8月 ～ 継続中
    東北大学大学院医学系研究科　緩和医療学分野　助教

  • 2023年4月 ～ 2023年7月
    東北大学　病院（医科診療部門） 緩和医療部　助教

  • 2022年12月 ～ 2023年3月
    東北大学　病院（医科診療部門） 緩和医療科　医員

  • 2022年1月 ～ 2022年11月
    北海道大学病院　呼吸器内科　医員 (肺がんグループ所属)

  • 2019年9月 ～ 2021年12月
    東北大学大学院医学系研究科　緩和医療学分野　特別研究生

  • 2018年4月 ～ 2019年8月
    北海道大学病院　内科Ⅰ　医員

  • 2017年4月 ～ 2018年3月
    社会福祉法人北海道社会事業協会 小樽病院　呼吸器内科　医師

  • 2016年4月 ～ 2017年3月
    医療法人 王子総合病院　呼吸器内科　後期研修医

  • 2015年4月 ～ 2016年3月
    独立行政法人地域医療機能推進機構 北海道病院　呼吸器センター呼吸器内科　後期研修医

︎全件表示 ︎最初の5件までを表示

学歴 3

  • 北海道大学大学院　医学院

    2019年4月 ～ 2022年3月

  • 旭川医科大学　医学部　医学科

    2007年4月 ～ 2013年3月

  • 北海道岩見沢東高等学校　普通科

    2004年4月 ～ 2007年3月

委員歴 2

  • 日本緩和医療学会　代議員

    2026年2月 ～ 継続中

  • 日本緩和医療学会　緩和ケア研修モジュール検討WG WG員

    2025年9月 ～ 継続中

所属学協会 7

  • 日本呼吸ケア・リハビリテーション学会

  • 日本結核・非結核性抗酸菌症学会

  • 日本肺癌学会

  • 日本臨床腫瘍学会

  • 日本緩和医療学会

  • 日本呼吸器学会

  • 日本内科学会

︎全件表示 ︎最初の5件までを表示

研究キーワード 6

  • がん薬物療法

  • 支持療法

  • 肺がん

  • 呼吸器内科学

  • 予後予測

  • 緩和医療学

研究分野 2

  • ライフサイエンス / 呼吸器内科学 /

  • ライフサイエンス / 内科学一般 / 緩和医療学

受賞 1

  1. 第111回北海道地方会学術奨励賞受賞

    2016年2月　日本呼吸器学会

論文 69

  1. Analysis of systemic opioid prescribing patterns for dyspnea in opioid-naïve cancer patients: a secondary analysis of a multicenter observational study in Japan. 国際誌

    Masashi Iida, Masanori Mori, Tomoo Ikari, Kozue Suzuki, Yukako Tanaka-Yagi, Hiroaki Watanabe, Takashi Ohmori, Yoshihisa Matsumoto, Takashi Yamaguchi

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer　34　(1)　53-53　2025年12月23日

    DOI： 10.1007/s00520-025-10264-8 　

    詳細を見る 詳細を閉じる

    PURPOSE: Opioids are recommended as first-line pharmacological therapy for cancer dyspnea. However, real-world opioid prescribing practices, including early dose adjustment for patients with impaired organ function, remain unclear. The purpose of this study was to clarify the real-world selection of opioid type and dosage adjustment for cancer-related dyspnea in opioid naïve patients, particularly in those with renal and liver dysfunction. METHODS: A secondary analysis of a multicenter observational study carried out at 12 palliative care facilities across Japan. The subjects were 224 hospitalized adult cancer patients who were opioid naïve and initiated regular systemic opioid therapy for dyspnea. The types of opioids (morphine, oxycodone, hydromorphone, fentanyl) and their dosages (oral morphine equivalent daily dose (OMEDD)) were collected from the initiation (T0) to 72 h later (T3). RESULTS: Morphine was the most frequently selected (132/224, 58.9%), followed by oxycodone (51/224, 22.8%), hydromorphone (30/224, 13.4%), and fentanyl (11/224, 4.9%). Mean OMEDD at T0 and T3 were 15.7 ± 7.7 mg and 20.0 ± 9.7mg for the morphine group, 14.1 ± 4.4 mg and 20.9 ± 10.7mg for oxycodone, 10.9 ± 3.0 mg and 15.8 ± 5.5mg for hydromorphone, and 18.5 ± 5.4 mg and 15.8 ± 7.0mg for fentanyl. In patients with renal dysfunction, oxycodone was the most frequently selected (15/26, 57.7%), and its dosage was increased over time, while the dosage of morphine and fentanyl was stable. In patients with liver dysfunction, morphine was the most frequently selected (12/24, 50.0%), with no significant dosage increases observed for all opioids. CONCLUSION: Morphine was the most frequently selected opioids for dyspnea in patients with cancer. Over the initial 72-h period, opioid dosages increased by 25-50% for most opioids. In patients with renal or liver dysfunction, opioid selection and dosage adjustments reflected clinical considerations of organ function.

  2. Clinical Characteristics and Treatment Outcomes of Terminal Dyspnea: A Multicenter Cohort Study. 国際誌

    Satoru Miwa, Masanori Mori, Kengo Imai, Tomoo Ikari, Hiroaki Watanabe, Yoshihisa Matsumoto, Yoshinobu Matsuda, Sayo Aiki, Takashi Yamaguchi

    Journal of palliative medicine　2025年12月12日

    DOI： 10.1177/10966218251403297 　

    詳細を見る 詳細を閉じる

    Context: The clinical characteristics of terminal dyspnea, including opioid effects, adverse events, and outcome acquisition rates, remain largely unexplored. Objectives: To investigate the clinical characteristics of terminal dyspnea in patients with cancer starting regular systemic opioid therapy, classified by clinician-predicted prognosis (days, weeks, months). Methods: This secondary analysis of a multicenter, prospective, observational study included adult patients with cancer who began regular systemic opioid therapy for dyspnea at 12 palliative care sites in Japan. Patients were classified into three prognostic groups: days (1-14 days), weeks (15-56 days), and months (>56 days) according to clinician-predicted survival [CPS]. Dyspnea intensity (numerical rating scale [NRS], Integrated Palliative care Outcome Scale [IPOS]) was assessed every 24 hours for 3 days. Adverse events and outcome acquisition rates were also evaluated. Results: A total of 402 patients were enrolled (days: 186, weeks: 174, months: 42). NRS and IPOS scores significantly improved across all groups. At 72 hours, mean NRS decreased from 7.2 to 4.5 in the days group, 6.5 to 3.9 in the weeks group, and 5.8 to 3.2 in the months group (p < 0.001 for all). Mean IPOS showed similar reductions. Somnolence and delirium increased in the days group, whereas such trends were not observed in the other groups. NRS acquisition rates declined in the days group (73.1-55.2%) but remained high in the weeks and months groups. IPOS acquisition rates were consistently high across all groups. Conclusion: Opioids alleviate dyspnea in patients with cancer regardless of CPS, but persistent symptoms remain. In imminently dying patients, adverse events were common and NRS was often not assessable. Further research should be conducted to optimize the assessment and management of patients with terminal dyspnea.

  3. Effectiveness of Opioid Titration for Terminal Dyspnea in Opioid-Naïve and -Tolerant Patients with Advanced Cancer: A Multicenter Prospective Cohort Study. 国際誌

    Masanori Mori, Takashi Yamaguchi, Kozue Suzuki, Yoshinobu Matsuda, Ryo Matsunuma, Hiroaki Watanabe, Tomoo Ikari, Yoshihisa Matsumoto, Kengo Imai, Naosuke Yokomichi, Satoru Miwa, Toshihiro Yamauchi, Soichiro Okamoto, Satoshi Inoue, Akira Inoue, David Hui, Tatsuya Morita, Eriko Satomi

    Journal of palliative medicine　2025年11月21日

    DOI： 10.1177/10966218251400154 　

    詳細を見る 詳細を閉じる

    Background: Terminal dyspnea is a distressing symptom in advanced cancer patients. Although opioids are standard treatment, their effectiveness may differ between opioid-naïve and -tolerant patients. Objectives: To evaluate responses to opioid titration for terminal dyspnea and assess differences in palliative care physicians' perceptions of opioid effectiveness between opioid-naïve and -tolerant patients. Design: A pre-planned secondary analysis of a multicenter prospective cohort study. Setting/Subjects: Advanced cancer patients (n = 108) with moderate to severe terminal dyspnea and an Eastern Cooperative Oncology Group performance status of 3-4, receiving continuous parenteral opioid infusions, were included and categorized as opioid-naïve (n = 48) or opioid-tolerant (n = 60). Measurements: Opioid doses were titrated in four predefined levels within 48 hours, with effectiveness assessed 6 hours post-titration using the Clinician Global Impression-Improvement scale. Opioid ineffectiveness was defined as the need for continuous sedatives or death without dyspnea relief, with doses recorded as the parenteral morphine-equivalent daily dose. Results: The mean age was 72 years, and lung cancer was present in 43 patients (40%). Opioid-naïve patients showed a 100% response after 12 titrations, while opioid-tolerant patients exhibited a 68% response after 34 titrations. At death or one month after treatment, opioids were determined to be ineffective in 8.3% of opioid-naïve and 38% of opioid-tolerant patients (p < 0.001). Median doses at ineffectiveness were 15 mg (IQR = 7.5-23) and 36 mg (IQR = 14-200), respectively. Conclusions: Opioid-tolerant patients showed a lower-level response and were more likely to experience ineffectiveness than opioid-naïve patients. Larger studies are needed to confirm these findings and improve terminal dyspnea management.

  4. Body Positioning for Dyspnea in Patients with Cancer with Unilateral Pleural Effusion: A Pilot Trial. 国際誌

    Jun Kako, Yoshinobu Matsuda, Tomoo Ikari, Kozue Suzuki, Ryo Tachikawa, Yoshihisa Matsumoto, Satoru Miwa, Masanori Mori, Tetsu Kobayashi, Hajime Fujimoto, Atsushi Tomaru, Hitoshi Sumitani, Akira Inoue, Rintaro Koike, Shota Kobayashi, Shunsuke Oyamada, Keisuke Ariyoshi, Takashi Yamaguchi

    Journal of palliative medicine　2025年9月16日

    DOI： 10.1177/10966218251377535 　

    詳細を見る 詳細を閉じる

    Background: Dyspnea is common in advanced cancer, especially with unilateral pleural effusion. Lateral positioning is widely used, but evidence of effectiveness is limited. Objectives: To assess the feasibility and short-term effects of affected-side-down (PLEUR-DOWN) versus affected-side-up (PLEUR-UP) positioning for dyspnea relief. Design: Multicenter randomized crossover pilot trial. Setting/Subjects: Ten patients with cancer with dyspnea were enrolled at seven hospitals in Japan. Methods: Patients (numerical rating scale [NRS] ≥ 3) were randomized to two sequences. Each position was maintained for five minutes within a washout period. The primary outcome was feasibility, assessed by completion, absence of carryover/period effects, and adherence. Secondary outcomes included NRS changes, patient preference, and safety. Results: All patients completed the trial. No significant carryover (p = 0.57) or period effects (p = 0.25) were found. Mean NRS difference favored PLEUR-DOWN (-0.9; p = 0.34). Half preferred PLEUR-DOWN. No adverse events occurred. Conclusions: The trial confirmed feasibility and supports further research.

  5. 腕時計型デバイスから得られる生体信号を用いた中等度以上のがん疼痛自動検出モデルの開発

    平山 英幸, 吉田 詩織, 佐々木 康之輔, 湯田 恵美, 升川 研人, 佐藤 麻美子, 猪狩 智生, 井上 彰, 川崎 芳英, 江幡 明子, 重田 昌吾, 宮下 光令

    Palliative Care Research　20　(Suppl.)　S.185-S.185　2025年7月

    出版者・発行元： (NPO)日本緩和医療学会

    eISSN：1880-5302

  6. The Effectiveness of Regular Opioids for Dyspnea Among Opioid-Tolerant Patients with Cancer: A Comparison of Increasing Baseline Opioids Versus Opioid Switch/Combination Therapy. 国際誌

    Kozue Suzuki, Yoshinobu Matsuda, Masanori Mori, Junichi Tasaki, Ryo Matsunuma, Tomoo Ikari, Satoru Miwa, Sayo Aiki, Yusuke Takagi, Daisuke Kiuchi, Shunsuke Oyamada, Keisuke Ariyoshi, Kota Kihara, Takashi Yamaguchi

    Journal of palliative medicine　28　(7)　924-930　2025年7月

    DOI： 10.1089/jpm.2024.0487 　

    詳細を見る 詳細を閉じる

    Background: Dyspnea is a common and distressing symptom in patients with cancer and often worsens even with the use of opioids for pain management. Understanding effective strategies for managing dyspnea in opioid-tolerant patients is essential for improving patient care. Objective: This study aimed to compare the effectiveness of different opioid treatment strategies for managing dyspnea in opioid-tolerant patients with cancer. Design: We conducted a secondary analysis of real-world data from a past observational study. Setting/Subjects: This study included 122 opioid-tolerant patients with cancer who experienced dyspnea. The patients were from 12 palliative care services across Japan. Measurements: We recorded patients' background, opioid usage, and dyspnea intensity using a numerical rating scale at baseline and every 24 hours for 72 hours after initiating treatment. Results: The overall response to treatment was 68%. The increase group (patients who increased their baseline opioid doses to manage dyspnea) saw a response of 63%, while the switch/combination group (patients who switched to another opioid or used a combination of opioids) saw a response of 73%. No significant differences were observed between the two groups. Multivariate analysis revealed that a dyspnea NRS score ≥7 was positively associated with dyspnea relief in all patients. Conclusions: Modification of systemic opioid administration is effective for dyspnea in opioid-tolerant patients with cancer, regardless of the treatment strategy employed. As this was an open-label observational study, randomized controlled trials are needed in the future.

  7. Evaluating the Efficacy of Thin Convex-probe Endobronchial Ultrasound Bronchoscope in Cadaveric Models. 国際誌

    Yuta Takashima, Naofumi Shinagawa, Tetsuaki Shoji, Masahiro Kashima, Hitoki Arisato, Daisuke Morinaga, Tomoo Ikari, Shotaro Ito, Kosuke Tsuji, Hirofumi Takahashi, Toshiaki Shichinohe, Satoshi Konno

    Journal of bronchology & interventional pulmonology　32　(3)　2025年7月1日

    DOI： 10.1097/LBR.0000000000001015 　

    詳細を見る 詳細を閉じる

    BACKGROUND: The convex-probe endobronchial ultrasound (CP-EBUS) bronchoscope is widely used in clinical practice. Despite improvements, the existing CP-EBUS remains limited in accessing areas beyond the mediastinum due to its large distal end diameter, long rigid tip segment, and oblique viewing angle. To address this limitation, Olympus Medical Systems Corporation developed the thin CP-EBUS (TCP-EBUS). This study aimed to compare the accessibility and puncturing ability of TCP-EBUS with existing CP-EBUS in cadaveric models. METHODS: Ten bronchoscopists conducted this study using 2 cadaveric models. The accessibility of TCP-EBUS was evaluated based on the number of bronchial generations that could be reached. To assess the puncturing ability of TCP-EBUS, needle punctures were performed on previously created simulated lesions in the segmental or subsegmental bronchial area, and puncture success rates were calculated. RESULTS: TCP-EBUS demonstrated greater accessibility than CP-EBUS in all segmental bronchi, with statistically significant differences observed in several bronchi (P<0.05). Puncture success rates for simulated lesions using TCP-EBUS were also significantly higher than those using CP-EBUS in both the segmental (85.0% vs. 60.0%, P<0.001) and subsegmental bronchial areas (84.4% vs. 38.9%, P<0.001). In a questionnaire survey, TCP-EBUS was perceived as significantly superior in terms of usability (P<0.05). CONCLUSION: TCP-EBUS has significantly improved both accessibility and puncture performance, providing an advantage over CP-EBUS in segmental and subsegmental bronchial areas. TCP-EBUS has the potential to expand the indications for endobronchial ultrasound-guided transbronchial needle aspiration.

  8. 低用量のセルペルカチニブが奏効したRET融合遺伝子陽性非小細胞肺癌の1例

    島田 琉海, 庄司 哲明, 高橋 宏典, 猪狩 智生, 高島 雄太, 古田 恵, 北井 秀典, 池澤 靖元, 榊原 純, 今野 哲, 伊藤 健一郎, 福土 将秀

    肺癌　65　(3)　205-205　2025年6月

    出版者・発行元： (NPO)日本肺癌学会

    ISSN：0386-9628

    eISSN：1348-9992

  9. Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer

    Jun Sakakibara-Konishi, Hirofumi Takahashi, Kenichiro Ito, Tomoo Ikari, Yasuyuki Ikezawa, Hidenori Kitai, Megumi Furuta, Yuta Takashima, Tetsuaki Shoji, Masahide Fukudo, Satoshi Konno

    Respiratory Medicine Case Reports　53　102176-102176　2025年

    出版者・発行元： Elsevier BV

    DOI： 10.1016/j.rmcr.2025.102176 　

    ISSN：2213-0071

  10. Preferred and Actual Places of Death Among Patients with Advanced Cancer: A Single-centre Cohort Study in Japan

    Tomoo Ikari, Yusuke Hiratsuka, Takayuki Oishi, Mitsunori Miyashita, Tatsuya Morita, Jennifer W. Mack, Yoshinari Okada, Natsuko Chiba, Chikashi Ishioka, Akira Inoue

    Indian Journal of Palliative Care　30　268-274　2024年8月23日

    出版者・発行元： Scientific Scholar

    DOI： 10.25259/ijpc_133_2024 　

    ISSN：0973-1075

    eISSN：1998-3735

    詳細を見る 詳細を閉じる

    Objectives: Achieving a ‘good death’ is one of the important goals of palliative care. Providing goal-concordant care and an environment tailored to the patient’s preferences can contribute to a ‘good death’. However, the concordance rate between the preferred and actual places of death among advanced cancer patients in Japan is less explored. This study aimed to identify the concordance between patients’ preferred and actual places of death and the associated factors among patients with advanced cancer in Japan. Materials and Methods: Patients with advanced cancer who underwent chemotherapy at Tohoku University Hospital between January 2015 and January 2016 were enrolled and followed up for 5 years. The enrolled patients were asked about their preference for their place of death. The response options were: “Own home,” “General ward” and “Palliative care unit (PCU).” We compared the actual place of death with the patient’s preference through a follow-up review of the medical records. Results: A total of 157 patients with advanced cancer were enrolled between January 2015 and January 2016. Of these patients, 22.9% (11/48) died at home according to their preference, 64.0% (16/25) in the general ward and 37.9% (11/29) in the PCU. Only thirty-seven (37.3%) patients died where they wanted, based on the comparison between patients’ preferences and actual places of death. Conclusion: The concordance rate between the preferred and actual places of death is not high in Japan. Improving concordance between patients’ preferences and actual places of death has the potential to improve end-of-life care.

  11. Potential Efficacy of Midazolam as Second-Line Treatment for Terminal Dyspnea in Patients with Cancer: Secondary Analysis of a Multicenter Prospective Cohort Study

    Satoru Miwa, Masanori Mori, Takashi Yamaguchi, Kozue Suzuki, Yoshinobu Matsuda, Ryo Matsunuma, Hiroaki Watanabe, Tomoo Ikari, Yoshihisa Matsumoto, Kengo Imai, Naosuke Yokomichi, Toshihiro Yamauchi, Soichiro Okamoto, Satoshi Inoue, Akira Inoue, Tatsuya Morita, Eriko Satomi

    Palliative Medicine Reports　5　(1)　225-233　2024年7月1日

    DOI： 10.1089/pmr.2023.0076 　

    eISSN：2689-2820

  12. Automatic Pain Detection Algorithm for Patients with Cancer Pain Using Wristwatch Wearable Devices.

    Hideyuki Hirayama, Shiori Yoshida, Konosuke Sasaki, Emi Yuda, Kento Masukawa, Mamiko Sato, Tomoo Ikari, Akira Inoue, Yoshihide Kawasaki, Mitsunori Miyashita

    EMBC　1-4　2024年

    DOI： 10.1109/EMBC53108.2024.10781536 　

  13. 次期細径超音波気管支鏡の挿入性及び穿刺性評価

    高島 雄太, 品川 尚文, 嘉島 相裕, 有里 仁希, 森永 大亮, 猪狩 智生, 伊藤 祥太郎, 辻 康介, 高橋 宏典, 庄司 哲明, 七戸 俊明, 今野 哲

    気管支学　45　(6)　444-445　2023年11月

    出版者・発行元： (一社)日本呼吸器内視鏡学会

    ISSN：0287-2137

    eISSN：2186-0149

  14. Cancer Pain Management in Patients Receiving Inpatient Specialized Palliative Care Services 査読有り

    Keita Tagami, Shih-Wei Chiu, Kazuhiro Kosugi, Hiroto Ishiki, Yusuke Hiratsuka, Masaki Shimizu, Masanori Mori, Emi Kubo, Tomoo Ikari, Sayaka Arakawa, Tetsuya Eto, Mayu Shimoda, Hideyuki Hirayama, Kaoru Nishijima, Kota Ouchi, Tatsunori Shimoi, Tomoko Shigeno, Takuhiro Yamaguchi, Mitsunori Miyashita, Tatsuya Morita, Akira Inoue, Eriko Satomi

    Journal of Pain and Symptom Management　2023年9月

    出版者・発行元： Elsevier BV

    DOI： 10.1016/j.jpainsymman.2023.09.015 　

    ISSN：0885-3924

  15. 疼痛に対してオピオイド使用中のがん患者呼吸困難に対するオピオイドの有効性についての観察研究

    鈴木 梢, 小山田 隼佑, 森 雅紀, 萩本 聡, 松田 能宣, 猪狩 智生, 三輪 聖, 松沼 亮, 小田切 拓也, 柏木 秀行, 里見 恵理子, 田中 佑加子, 松本 禎久, 鶴賀 哲史, 田中 桂子, 山口 崇

    Palliative Care Research　18　(Suppl.)　S198-S198　2023年6月

    出版者・発行元： (NPO)日本緩和医療学会

    eISSN：1880-5302

  16. 次期細径超音波気管支鏡の挿入性及び穿刺性評価

    高島 雄太, 品川 尚文, 嘉島 相裕, 有里 仁希, 森永 大亮, 猪狩 智生, 伊藤 祥太郎, 辻 康介, 高橋 宏典, 庄司 哲明, 七戸 俊明, 今野 哲

    気管支学　45　(Suppl.)　S257-S257　2023年6月

    出版者・発行元： (一社)日本呼吸器内視鏡学会

    ISSN：0287-2137

    eISSN：2186-0149

  17. Do types of opioids matter for terminal cancer dyspnea? A preliminary multicenter cohort study. 国際誌

    Masanori Mori, Takashi Yamaguchi, Kozue Suzuki, Yoshinobu Matsuda, Ryo Matsunuma, Hiroaki Watanabe, Tomoo Ikari, Yoshihisa Matsumoto, Kengo Imai, Naosuke Yokomichi, Satoru Miwa, Toshihiro Yamauchi, Soichiro Okamoto, Satoshi Inoue, Akira Inoue, David Hui, Tatsuya Morita, Eriko Satomi

    Journal of pain and symptom management　66　(2)　e177-e184　2023年4月18日

    DOI： 10.1016/j.jpainsymman.2023.04.009 　

    詳細を見る 詳細を閉じる

    CONTEXT: Dyspnea is among the most distressing symptoms in the last weeks to days of life (terminal dyspnea). While physicians frequently use parenteral opioids other than morphine for terminal dyspnea, little is known about their effects in cancer patients. OBJECTIVES: To explore the effectiveness and safety of parenteral morphine, oxycodone, and hydromorphone for cancer patients with terminal dyspnea. METHODS: This was a secondary analysis of a multicenter cohort study that consecutively enrolled advanced cancer patients with moderate/severe terminal dyspnea. Participating palliative care physicians initiated parenteral opioids (morphine/oxycodone/hydromorphone), utilizing a standardized treatment algorithm. We examined the dyspnea intensity (Integrated Palliative care Outcome Scale (IPOS)) at 24 and 48 hours. RESULTS: Of 108 patients (mean age=72), 66 (61%), 34 (32%), and 8 (7.4%) received morphine, oxycodone, and hydromorphone, respectively. At 24 hours, mean dyspnea IPOS scores significantly decreased from 3.0 (standard error (SE)=0.1) at the baseline to 1.6 (0.1), 2.9 (0.1) to 2.0 (0.2), and 3.5 (0.2) to 1.2 (0.4) in the morphine (p<0.001), oxycodone (p<0.001), and hydromorphone (p=0.011) groups, respectively. At 48 hours, the IPOS scores significantly reduced from 2.9 (0.1) at the baseline to 1.4 (0.1), 2.9 (0.1) to 1.6 (0.2), and 3.5 (0.2) to 1.2 (0.2) in the morphine (p<0.001), oxycodone (p<0.001), and hydromorphone (p=0.004) groups, respectively. No significant differences in mean scores were found among the three groups at 24 (p=0.080) and 48 hours (p=0.322). Adverse events were rare. CONCLUSION: Parenteral morphine, oxycodone, and hydromorphone may be similarly effective and safe for cancer patients with terminal dyspnea.

  18. Current Management Options for Dyspnea in Cancer Patients. 国際誌 招待有り 査読有り

    Masanori Mori, Satoru Miwa, Tomoo Ikari, Jun Kako, Takaaki Hasegawa, Ryo Matsunuma, Kozue Suzuki, Yoshinobu Matsuda, Hiroaki Watanabe, Tatsuya Morita, Takashi Yamaguchi

    Current treatment options in oncology　2023年4月11日

    DOI： 10.1007/s11864-023-01081-4 　

    詳細を見る 詳細を閉じる

    Dyspnea is one of the most frequent and distressing symptoms in patients with advanced cancer. As dyspnea deteriorates patients' quality of life markedly and tends to worsen as the disease progresses, comprehensive assessment and timely treatment of the underlying etiologies are essential. International guidelines recommend various non-pharmacological and pharmacological management options. However, there is a scarcity of confirmatory clinical trials on cancer dyspnea, and the overall level of evidence is weak. Recently, observational and survey studies indicated a wide range of practice patterns of palliative care specialists, providing important insight into the real-world management of dyspnea. In this paper, we summarize current management options for dyspnea in cancer patients, highlight major controversies in the literature, and propose future research directions toward quality care for patients with dyspnea and their families.

  19. 当科におけるPD-L1陰性非小細胞肺癌に対する免疫チェックポイント阻害薬治療についての後方視的検討

    田上 敬太, 菊地 英毅, 庄司 哲明, 吉川 修平, 黒木 俊宏, 嘉島 相裕, 高木 統一郎, 三浦 瞬, 猪狩 智生, 小熊 昂, 古田 恵, 高島 雄太, 朝比奈 肇, 菊地 順子, 榊原 純, 品川 尚文, 今野 哲

    肺癌　63　(2)　126-127　2023年4月

    出版者・発行元： (NPO)日本肺癌学会

    ISSN：0386-9628

    eISSN：1348-9992

  20. 化学放射線療法+デュルバルマブ療法を施行後に病勢進行となった非小細胞肺癌の次治療の後方視的検討

    嘉島 相裕, 庄司 哲明, 古田 恵, 吉川 修平, 黒木 俊宏, 田上 敬太, 高木 統一郎, 三浦 瞬, 小熊 昂, 猪狩 智生, 高島 雄太, 朝比奈 肇, 菊地 順子, 菊地 英毅, 榊原 純, 品川 尚文, 今野 哲

    肺癌　63　(2)　127-127　2023年4月

    出版者・発行元： (NPO)日本肺癌学会

    ISSN：0386-9628

    eISSN：1348-9992

  21. RET融合遺伝子陽性肺腺癌に対してセルペルカチニブ投与後に多彩な有害事象を呈した症例

    関 萌花, 猪狩 智生, 榊原 純, 吉川 修平, 黒木 俊宏, 田上 敬太, 嘉島 相裕, 高木 統一郎, 三浦 瞬, 小熊 昂, 高島 雄太, 古田 恵, 庄司 哲明, 朝比奈 肇, 菊地 順子, 菊地 英毅, 品川 尚文, 今野 哲, 伊藤 健一郎

    肺癌　63　(2)　128-128　2023年4月

    出版者・発行元： (NPO)日本肺癌学会

    ISSN：0386-9628

    eISSN：1348-9992

  22. 非小細胞肺癌での化学放射線+デュルバルマブ療法後の免疫チェックポイント阻害剤再投与の後方視的検討

    嘉島 相裕, 庄司 哲明, 古田 恵, 猪狩 智生, 高島 雄太, 朝比奈 肇, 菊地 順子, 菊地 英毅, 榊原 純, 今野 哲

    日本呼吸器学会誌　12　(増刊)　278-278　2023年3月

    出版者・発行元： (一社)日本呼吸器学会

    ISSN：2186-5876

    eISSN：2186-5884

  23. Systemic opioids for dyspnea in cancer patients: A real-world observational study

    Takashi Yamaguchi, Ryo Matsunuma, Yoshinobu Matsuda, Junichi Tasaki, Tomoo Ikari, Satoru Miwa, Sayo Aiki, Yusuke Takagi, Daisuke Kiuchi, Kozue Suzuki, Shunsuke Oyamada, Keisuke Ariyoshi, Kota Kihara, Masanori Mori

    Journal of Pain and Symptom Management　2023年1月

    出版者・発行元： Elsevier BV

    DOI： 10.1016/j.jpainsymman.2022.12.146 　

    ISSN：0885-3924

  24. Effectiveness and safety of opioids for dyspnea in patients with lung cancer: secondary analysis of multicenter prospective observational study. 国際誌

    Yoshihiko Taniguchi, Yoshinobu Matsuda, Masanori Mori, Madoka Ito, Tomoo Ikari, Akihiro Tokoro, Sayo Aiki, Shunya Hoshino, Daisuke Kiuchi, Kozue Suzuki, Yuko Igarashi, Takuya Odagiri, Kiyofumi Oya, Emi Kubo, Takashi Yamaguchi

    Translational lung cancer research　11　(12)　2395-2402　2022年12月

    DOI： 10.21037/tlcr-22-512 　

    詳細を見る 詳細を閉じる

    BACKGROUND: Patients with lung cancer are more likely to have comorbidities [e.g., interstitial lung disease (ILD)], chronic obstructive pulmonary disease) and metastases that may affect dyspnea and the effectiveness and safety of opioids for dyspnea than other cancer types. Therefore, this study examined the effectiveness and safety of opioids for dyspnea, among the patients with lung cancer. METHODS: The present study is a secondary analysis of a multicenter prospective observational study examining the effectiveness and safety of opioids for dyspnea in patients with cancer in Japan. For this secondary analysis, patients with lung cancer with a documented dyspnea Numerical Rating Scale (NRS) at baseline were included. The primary outcome was dyspnea NRS, and Integrated Palliative care Outcome Scale/Support Team Assessment Schedule (IPOS/STAS) scores change between baseline and 24 hours after baseline. As secondary outcomes, we investigated the predictors of opioid effectiveness for dyspnea improvement and adverse events (nausea, somnolence, and delirium). RESULTS: This study analyzed 124 patients with lung cancer with known dyspnea NRS at baseline. The median age was 74, and the Eastern Cooperative Oncology Group performance status of 107 patients were 3-4. Both NRS and IPOS/STAS score of dyspnea significantly improved 24 hours after opioid initiation [-1.64, 95% confidence interval (CI): -2.12 to -1.17, P<0.001; -1.03; 95% CI: -1.21 to -0.85, P<0.001; respectively]. Moreover, the improvement of NRS score was greater than the minimal clinically important difference of 1 point. In the multivariate logistic regression analysis, ILD was significantly associated with a better improvement [(hazard ratio (HR): 3.39, 95% CI: 1.34-11.09, P=0.043]. Somnolence was the most common grade 3-4 adverse event (n=16), followed by delirium (n=9). CONCLUSIONS: Opioids were effective and safe for treating dyspnea in patients with lung cancer. Furthermore, lung cancer patients with ILD may benefit more from opioids.

  25. The feasibility and effects of a pharmacological treatment algorithm for cancer patients with terminal dyspnea: A multicenter cohort study

    Masanori Mori, Takashi Yamaguchi, Kozue Suzuki, Yoshinobu Matsuda, Ryo Matsunuma, Hiroaki Watanabe, Tomoo Ikari, Yoshihisa Matsumoto, Kengo Imai, Naosuke Yokomichi, Satoru Miwa, Toshihiro Yamauchi, Soichiro Okamoto, Satoshi Inoue, Akira Inoue, Tatsuya Morita, Eriko Satomi

    Cancer Medicine　12　(5)　5397-5408　2022年10月19日

    出版者・発行元： Wiley

    DOI： 10.1002/cam4.5362 　

    ISSN：2045-7634

    eISSN：2045-7634

  26. Factors associated with good death of patients with advanced cancer: a prospective study in Japan 国際誌

    Tomoo Ikari, Yusuke Hiratsuka, Shao-Yi Cheng, Mitsunori Miyashita, Tatsuya Morita, Masanori Mori, Yu Uneno, Koji Amano, Yuko Uehara, Takashi Yamaguchi, Isseki Maeda, Akira Inoue

    Supportive Care in Cancer　2022年9月20日

    出版者・発行元： Springer Science and Business Media LLC

    DOI： 10.1007/s00520-022-07363-1 　

    ISSN：0941-4355

    eISSN：1433-7339

    詳細を見る 詳細を閉じる

    PURPOSE: It is important for palliative care providers to identify what factors are associated with a "good death" for patients with advanced cancer. We aimed to identify factors associated with a "good death" evaluated by the Good Death Scale (GDS) score among inpatients with advanced cancer in palliative care units (PCUs) in Japan. METHODS: The study is a sub-analysis of a multicenter prospective cohort study conducted in Japan. All variables were recorded on a structured data collecting sheet designed for the study. We classified each patient into better GDS group or worse GDS group, and examined factors associated with better GDS using multivariate analysis. RESULTS: Between January and December 2017, 1896 patients were enrolled across 22 PCUs in Japan. Among them, a total of 1157 patients were evaluated. Five variables were significantly associated with a better GDS score in multivariate analysis: preferred place of death at PCU (odds ratio [OR] 2.85; 95% confidence interval [CI] 1.72-4.71; p < 0.01), longer survival time (OR 1.02; 95% CI 1.00-1.03; p < 0.01), not sudden death (OR 1.96; 95% CI 1.27-3.04; p < 0.01), better spiritual well-being in the last 3 days in life (OR 0.53; 95% CI 0.42-0.68; p < 0.01), and better communication between patient and family (OR 0.81; 95% CI 0.66-0.98; p = 0.03). CONCLUSIONS: We identified factors associated with a "good death" using GDS among advanced cancer patients in Japanese PCUs. Recognition of factors associated with GDS could help to improve the quality of end-of-life care.

  27. Relationship between dyspnoea and related factors in patients with cancer: a cross-sectional study 査読有り

    Yoshinobu Matsuda, Hideaki Hasuo, Keiichi Narita, Hiromichi Matsuoka, Ryo Morita, Daisuke Kiuchi, Tomoo Ikari, Tetsuo Hori, Koya Okazaki, Kiyohiro Sakai, Sayo Aiki, Hiroko Okabayashi, Shunsuke Oyamada, Keisuke Ariyoshi, Akihiro Tokoro, Mikihiko Fukunaga

    BMJ Supportive & Palliative Care　bmjspcare-2021　2022年7月19日

    DOI： 10.1136/bmjspcare-2021-003484 　

    ISSN：2045-435X

    eISSN：2045-4368

  28. 緩和ケア病棟入棟のための面談を実施した患者の在宅医療導入後の転帰 後ろ向きカルテ調査

    田中 雄太, 田上 恵太, 三浦 洋子, 齋藤 明美, 佐藤 麻美子, 佐竹 宣明, 猪狩 智生, 珠蘭其其格, 町田 雄一郎, 山内 悦子, 井上 彰

    Palliative Care Research　17　(Suppl.)　S.354-S.354　2022年7月

    出版者・発行元： (NPO)日本緩和医療学会

    eISSN：1880-5302

  29. がん患者の呼吸困難に関連する因子の相互作用および因果関係に関する横断研究 JORTC-PAL19

    松田 能宣, 蓮尾 英明, 成田 慶一, 松岡 弘道, 守田 亮, 木内 大佑, 猪狩 智生, 堀 哲雄, 岡崎 航也, 酒井 清裕, 相木 佐代, 岡林 比呂子, 小山田 隼佑, 有吉 恵介, 所 昭宏, 福永 幹彦

    Palliative Care Research　17　(Suppl.)　S.182-S.182　2022年7月

    出版者・発行元： (NPO)日本緩和医療学会

    eISSN：1880-5302

  30. 専門的緩和ケアサービスによるがん疼痛の症状緩和治療に関する実態調査 多施設共同前向き観察研究

    田上 恵太, 小杉 和博, 石木 寛人, 平塚 裕介, 清水 正樹, 森 雅紀, 邱 士い, 下田 真優, 平山 英幸, 佐藤 麻美子, 松田 泰史, 猪狩 智生, 宮下 光令, 山口 拓洋, 井上 彰, 里見 絵理子

    Palliative Care Research　17　(Suppl.)　S.210-S.210　2022年7月

    出版者・発行元： (NPO)日本緩和医療学会

    eISSN：1880-5302

  31. Case Report: Hereditary Fibrosing Poikiloderma With Tendon Contractures, Myopathy, and Pulmonary Fibrosis (POIKTMP) Presenting With Liver Cirrhosis and Steroid-Responsive Interstitial Pneumonia

    Michiko Takimoto-Sato, Toshinari Miyauchi, Masaru Suzuki, Hideyuki Ujiie, Toshifumi Nomura, Tomoo Ikari, Tomohiko Nakamura, Kei Takahashi, Machiko Matsumoto-Sasaki, Hirokazu Kimura, Hiroki Kimura, Yuichiro Matsui, Takashi Kitagataya, Ren Yamada, Kazuharu Suzuki, Akihisa Nakamura, Masato Nakai, Takuya Sho, Koji Ogawa, Naoya Sakamoto, Naoko Yamaguchi, Noriyuki Otsuka, Utano Tomaru, Satoshi Konno

    Frontiers in Genetics　13　2022年5月5日

    出版者・発行元： Frontiers Media SA

    DOI： 10.3389/fgene.2022.870192 　

    eISSN：1664-8021

    詳細を見る 詳細を閉じる

    Background: Hereditary fibrosing poikiloderma with tendon contractures, myopathy, and pulmonary fibrosis (POIKTMP) is an extremely rare disease caused by mutations in FAM111B, and only approximately 30 cases have been reported worldwide. Some patients develop interstitial pneumonia, which may lead to progressive pulmonary fibrosis and poor prognosis. However, no effective treatment for interstitial pneumonia associated with POIKTMP has been reported. Here, we report an autopsy case of POIKTMP, wherein interstitial pneumonia was improved by corticosteroids. Case Presentation: A 44-year-old Japanese man was referred to our hospital due to poikiloderma, hypotrichosis, and interstitial pneumonia. He developed progressive poikiloderma and muscle weakness since infancy. He also had tendon contractures, short stature, liver cirrhosis, and interstitial pneumonia. Mutation analysis of FAM111B revealed a novel and de novo heterozygous missense mutation, c.1886T &amp;gt; G (p(Phe629Cys)), through which we were able to diagnose the patient with POIKTMP. 3 years after the POIKTMP diagnosis, interstitial pneumonia had worsened. After 2 weeks of administrating 40 mg/day of prednisolone, his symptoms and lung shadows improved. However, he subsequently developed severe hepatic encephalopathy and eventually died of respiratory failure due to bacterial pneumonia and pulmonary edema. Autopsy revealed an unclassifiable pattern of interstitial pneumonia, as well as the presence of fibrosis and fatty degeneration in several organs, including the liver, kidney, skeletal muscle, heart, pancreas, and thyroid. Conclusions: We report a case of POIKTMP in which interstitial pneumonia was improved by corticosteroids, suggesting that corticosteroids could be an option for the treatment of interstitial pneumonia associated with this disease.

  32. 肺病変にステロイドが奏功したPOIKTMPの1例(アンコール演題)

    佐藤 理子, 鈴木 雅, 猪狩 智生, 中村 友彦, 高橋 桂, 佐々木 真知子, 木村 孔一, 木村 裕樹, 宮内 俊成, 乃村 俊史, 氏家 英之, 山口 直子, 大塚 紀幸, 外丸 詩野, 今野 哲

    日本呼吸器学会誌　11　(増刊)　272-272　2022年4月

    出版者・発行元： (一社)日本呼吸器学会

    ISSN：2186-5876

    eISSN：2186-5884

  33. Morphine May Contribute to Improving Respiratory Failure in Severe COVID-19: A Case Report. 査読有り

    Tomoo Ikari

    Indian journal of palliative care　28　(2)　221-223　2022年4月1日

    DOI： 10.25259/ijpc_132_2021 　

    詳細を見る 詳細を閉じる

    At present, the world is undergoing successive waves of the COVID-19 pandemic. When COVID-19 becomes severe, it causes respiratory failure and symptoms of dyspnoea. The patient's dyspnoea worsens to the IPOS of 3. One COVID-19 patient admitted to our medical institution developed severe illness characterised by hypoxaemia and dyspnoea. In addition to disease-modifying treatments such as remdesivir and dexamethasone, we administered morphine to relieve his dyspnoea. Surprisingly, we observed an improvement in both hypoxaemia and dyspnoea.

  34. 肺病変にステロイドが奏功したPOIKTMPの1例(アンコール演題)

    佐藤 理子, 鈴木 雅, 猪狩 智生, 中村 友彦, 高橋 桂, 佐々木 真知子, 木村 孔一, 木村 裕樹, 宮内 俊成, 乃村 俊史, 氏家 英之, 山口 直子, 大塚 紀幸, 外丸 詩野, 今野 哲

    日本呼吸器学会誌　11　(増刊)　272-272　2022年4月

    出版者・発行元： (一社)日本呼吸器学会

    ISSN：2186-5876

    eISSN：2186-5884

  35. Predictive Factors for the Development of Dyspnea Within 7 Days After Admission Among Terminally Ill Cancer Patients. 国際誌

    Ryo Matsunuma, Takashi Yamaguchi, Masanori Mori, Tomoo Ikari, Kozue Suzuki, Yoshinobu Matsuda, Yoshihisa Matsumoto, Hiroaki Watanabe, Koji Amano, Rena Kamura, Yoshiyuki Kizawa

    The American journal of hospice & palliative care　39　(4)　413-420　2022年4月

    DOI： 10.1177/10499091211028817 　

    詳細を見る 詳細を閉じる

    BACKGROUND: Predictive factors for the development of dyspnea have not been reported among terminally ill cancer patients. OBJECTIVE: This current study aimed to identify the predictive factors attributed to the development of dyspnea within 7 days after admission among patients with cancer. METHODS: This was a secondary analysis of a multicenter prospective observational study on the dying process among patients admitted in inpatient hospices/palliative care units. Patients were divided into 2 groups: those who developed dyspnea (development group) and those who did not (non-development group). To determine independent predictive factors, univariate and multivariate analyses using the logistic regression model were performed. RESULTS: From January 2017 to December 2017, 1159 patients were included in this analysis. Univariate analysis showed that male participants, those with primary lung cancer, ascites, and Karnofsky Performance Status score (KPS) of ≤40, smokers, and benzodiazepine users were significantly higher in the development group. Multivariate analysis revealed that primary lung cancer (odds ratio [OR]: 2.80, 95% confidence interval [95% CI]: 1.47-5.31; p = 0.002), KPS score (≤40) (OR: 1.84, 95% CI: 1.02-3.31; p = 0.044), and presence of ascites (OR: 2.34, 95% CI: 1.36-4.02; p = 0.002) were independent predictive factors for the development of dyspnea. CONCLUSIONS: Lung cancer, poor performance status, and ascites may be predictive factors for the development of dyspnea among terminally ill cancer patients. However, further studies should be performed to validate these findings.

  36. The Possibility of Conducting a Clinical Trial on Palliative Care: A Survey of Whether a Clinical Study on Cancer Dyspnea Is Acceptable to Cancer Patients and Their Relatives. 国際誌

    Kozue Suzuki, Tomoo Ikari, Ryo Matsunuma, Yoshinobu Matsuda, Yoshihisa Matsumoto, Satoru Miwa, Masanori Mori, Takashi Yamaguchi, Hiroaki Watanabe, Keiko Tanaka

    Journal of pain and symptom management　62　(6)　1262-1272　2021年12月

    DOI： 10.1016/j.jpainsymman.2021.05.012 　

    詳細を見る 詳細を閉じる

    CONTEXT: Conducting randomized controlled trials on palliative care is difficult owing to barriers like fragility of the patients' health status and health care providers' concerns for patients. However, quality randomized controlled trials are required for care improvement. OBJECTIVES: To investigate the willingness of cancer patients and their relatives to participate in a clinical study on cancer dyspnea and identify feasible clinical study designs for this condition. METHODS: A nationwide, cross-sectional, web-based survey was conducted with 206 cancer patients and 206 relatives of cancer patients. Their willingness to participate in clinical studies on cancer dyspnea and factors influencing this willingness were assessed in two scenarios: outpatients receiving anticancer treatment and terminally ill inpatients. RESULTS: About 23% patients and 23% relatives were willing to participate in clinical trials while 40% and 32%, respectively, were unwilling. Factors related to patient participation were quick and easy trials (outpatient 57%, terminally ill 53%) and oral medication with minimal potential side effects (outpatient 48%). Factors related to unwillingness to participate were placebo-controlled trials (outpatient 51%, terminally ill 50%), disagreements about participation between patients and families (outpatient 49%, terminally ill 49%), and continuous injections (outpatient 61%, terminally ill 47%). Compared to patients, relatives responded more reluctantly, especially for patients in terminal care. Conversely, patients were less reluctant in the terminal setting than the outpatient setting. CONCLUSION: Some patients and relatives were reluctant to participate in clinical trials on cancer dyspnea. Thus, trials need to be minimally invasive, quick, and fully explained to and understood by patients and families.

  37. Is the 1-day surprise question a useful screening tool for predicting prognosis in patients with advanced cancer?-a multicenter prospective observational study. 国際誌

    Tomoo Ikari, Yusuke Hiratsuka, Takuhiro Yamaguchi, Masanori Mori, Yu Uneno, Tomohiko Taniyama, Yosuke Matsuda, Kiyofumi Oya, Koji Amano, Keita Tagami, Akira Inoue

    Annals of palliative medicine　10　(11)　11278-11287　2021年11月

    DOI： 10.21037/apm-21-1718 　

    詳細を見る 詳細を閉じる

    BACKGROUND: For cancer patients nearing death, the prediction of their prognosis by physicians is crucial. This study examined the usefulness of the 1-Day Surprise Question (1DSQ). METHODS: This study was conducted as part of a multicenter prospective observational study. The physicians answered the 1DSQ "Would I be surprised if this patient died in the next 1 day?" when patients have palliative performance scale (PPS) ≤20. We calculated the sensitivity and specificity of the 1DSQ. Moreover, using multivariate analysis, we evaluated the characteristics of patients who died among those whose physicians answered the 1DSQ as "not surprised". RESULTS: Overall, 1,896 patients were enrolled, and 1,411 (74.4%) were analyzed between January and December 2017. Among these, 847 (60.0%) patients were placed in the "not surprised" group. The sensitivity, specificity, and positive and negative predictive values of the 1DSQ were 82.0% [95% confidence interval (CI): 77.5-85.8%], 45.5% (95% CI: 44.4-46.4%), 27.4% (95% CI: 25.9-28.7%), and 91.0% (95% CI: 88.9-92.9%), respectively. Multivariate analysis revealed that urine output over last 12 hours <100 mL, decreased response to visual stimuli, respiration with mandibular movement, pulselessness of radial artery, and saturation of percutaneous oxygen <90% were characteristics of patients who died as predicted by the physicians. CONCLUSIONS: The 1DSQ is a helpful screening tool for identifying cancer patients with impending death.

  38. 緩和ケア領域の臨床試験に対するがん患者・家族の意向に関する大規模調査 症状別の参加意向、症状評価スケールの答えやすさ、同意取得方法について

    鈴木 梢, 猪狩 智生, 松田 能宣, 松沼 亮, 三輪 聖, 森 雅紀, 山口 崇, 渡邊 紘章, 松本 禎久, 田中 桂子

    Palliative Care Research　16　(Suppl.)　S430-S430　2021年6月

    出版者・発行元： (NPO)日本緩和医療学会

    eISSN：1880-5302

  39. 緩和ケア領域の臨床試験に対するがん患者・家族の意向に関する大規模調査 実現可能な終末期の呼吸困難に関する臨床試験について探索する

    鈴木 梢, 猪狩 智生, 松田 能宣, 松沼 亮, 三輪 聖, 森 雅紀, 山口 崇, 渡邊 紘章, 松本 禎久, 田中 桂子

    Palliative Care Research　16　(Suppl.)　S431-S431　2021年6月

    出版者・発行元： (NPO)日本緩和医療学会

    eISSN：1880-5302

  40. 訪問看護師のアンケート調査による、緩和ケアの専門家が不在の地域における緩和ケアアウトリーチの有効性

    佐藤 麻美子, 田上 恵太, 猪狩 智生, 佐竹 宣明, 田上 佑輔, 井上 彰

    Palliative Care Research　16　(Suppl.)　S435-S435　2021年6月

    出版者・発行元： (NPO)日本緩和医療学会

    eISSN：1880-5302

  41. Factors influencing spiritual well-being in terminally ill cancer inpatients in Japan. 国際誌

    Yusuke Hiratsuka, Sang-Yeon Suh, Isseki Maeda, Tatsuya Morita, Masanori Mori, Satoko Ito, Tomohiro Nishi, Takayuki Hisanaga, Tetsuji Iriyama, Keisuke Kaneishi, Tomoo Ikari, Keita Tagami, Akira Inoue

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer　29　(5)　2795-2802　2021年5月

    DOI： 10.1007/s00520-020-05802-5 　

    詳細を見る 詳細を閉じる

    PURPOSE: Spiritual well-being is very important in patients undergoing palliative care. Although psychosocial factors have been suggested to be associated with spiritual well-being, the relationship between physical signs and spiritual well-being has not been fully elucidated. The aim of this study was to explore diverse factors associated with spiritual well-being among palliative care patients in Japan. METHODS: This study is a secondary analysis of a multicenter prospective cohort study involving patients admitted to palliative care units in Japan. Physicians recorded all data prospectively on a structured sheet designed for the study. The spiritual well-being score was measured using the Integrated Palliative Outcome Scale after patients' death in regard to symptoms over the previous 3 days. We classified each patient into "better" score (0-1) and "worse" score (2-4) groups and examined diverse factors associated with spiritual well-being. RESULTS: Among the 1896 patients enrolled, 1313 were evaluated. In the multivariate analysis, seven variables were significantly associated with "worse" score: worse spiritual well-being on admission (2-4) (p < 0.0001), younger age (< 80) (p = 0.0001), hyperactive delirium over 3 days before death (mild/moderate/severe) (p = 0.0001), expressed wish for hastened death (yes) (p = 0.0006), worse communication among patients and families (Support Team Assessment Schedule score 2-4) (p = 0.0008), pleural effusion (present) (p = 0.037), and marital status (unmarried) (p = 0.0408). CONCLUSION: Recognizing factors associated with spiritual well-being is potentially useful for identifying high-risk groups with lower spiritual well-being at the end of life. Further study is required to investigate factors associated with patient-reported spiritual well-being.

  42. "3-Day Surprise Question" to predict prognosis of advanced cancer patients with impending death: Multicenter prospective observational study. 国際誌

    Tomoo Ikari, Yusuke Hiratsuka, Takuhiro Yamaguchi, Isseki Maeda, Masanori Mori, Yu Uneno, Tomohiko Taniyama, Yosuke Matsuda, Kiyofumi Oya, Keita Tagami, Akira Inoue

    Cancer medicine　10　(3)　1018-1026　2021年2月

    DOI： 10.1002/cam4.3689 　

    詳細を見る 詳細を閉じる

    BACKGROUND: The study aimed to clarify the efficacy of the "3-Day Surprise Question (3DSQ)" in predicting the prognosis for advanced cancer patients with impending death. PATIENTS AND METHODS: This study was a part of multicenter prospective observational study which investigated the dying process in advanced cancer patients in Japan. For patients with a Palliative Performance Scale ≤20, the 3DSQ "Would I be surprised if this patient died in the next 3 days?" was answered by their physicians. In addition to the sensitivity and specificity of the 3DSQ, the characteristics of patients who survived longer than expected were examined via multivariate analysis. RESULTS: Among the 1896 patients enrolled, 1411 were evaluated. Among 1179 (83.6%) patients who were classified into the "Not surprised" group, 636 patients died within 3 days. Among 232 (16.4%) patients of "Yes surprised" group, 194 patients lived longer than 3 days. The sensitivity, specificity, positive predictive value, and negative predictive value of the 3DSQ were 94.3% (95% confidence interval [CI]: 92.7% to 95.8%), 26.3% (95% CI: 24.8% to 27.6%), 53.9% (95% CI: 53.0% to 54.7%), and 83.6% (95% CI: 78.7% to 87.7%), respectively. Multivariate analysis showed palpable radial artery, absent respiration with mandibular movement, SpO2 ≥ 90%, opioid administration, and no continuous deep sedation as characteristics of patients who lived longer than expected. CONCLUSIONS: The 3-Day Surprise Question can be a useful screening tool to identify advanced cancer patients with impending death.

  43. 当科におけるEGFR遺伝子変異陽性非小細胞肺癌に対するデュルバルマブ使用症例の後方視的検討

    辻 康介, 水柿 秀紀, 伊藤 祥太郎, 猪狩 智生, 佐藤 峰嘉, 高橋 宏典, 國崎 守, 高島 雄太, 古田 恵, 庄司 哲明, 朝比奈 肇, 菊地 順子, 菊地 英毅, 榊原 純, 品川 尚文, 今野 哲

    肺癌　60　(6)　638-638　2020年10月

    出版者・発行元： (NPO)日本肺癌学会

    ISSN：0386-9628

    eISSN：1348-9992

  44. 当科におけるEGFR遺伝子変異陽性非小細胞肺癌に対するデュルバルマブ使用症例の後方視的検討

    辻 康介, 水柿 秀紀, 伊藤 祥太郎, 猪狩 智生, 佐藤 峰嘉, 高橋 宏典, 國崎 守, 高島 雄太, 古田 恵, 庄司 哲明, 朝比奈 肇, 菊地 順子, 菊地 英毅, 榊原 純, 品川 尚文, 今野 哲

    肺癌　60　(6)　638-638　2020年10月

    出版者・発行元： (NPO)日本肺癌学会

    ISSN：0386-9628

    eISSN：1348-9992

  45. COVID-19患者の呼吸器症状への対応に関する手引きの作成

    松沼 亮, 猪狩 智生, 鈴木 梢, 松田 能宣, 松本 禎久, 森 雅紀, 山口 崇, 渡邊 紘章

    Palliative Care Research　15　(Suppl.)　S1257-S1257　2020年8月

    出版者・発行元： (NPO)日本緩和医療学会

    eISSN：1880-5302

  46. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302). 国際誌

    Hajime Asahina, Satoshi Oizumi, Kei Takamura, Toshiyuki Harada, Masao Harada, Hiroshi Yokouchi, Kenya Kanazawa, Yuka Fujita, Tetsuya Kojima, Fumiko Sugaya, Hisashi Tanaka, Ryoichi Honda, Eiki Kikuchi, Tomoo Ikari, Takahiro Ogi, Kaoruko Shimizu, Masaru Suzuki, Satoshi Konno, Hirotoshi Dosaka-Akita, Hiroshi Isobe, Masaharu Nishimura

    Lung cancer (Amsterdam, Netherlands)　138　65-71　2019年12月

    DOI： 10.1016/j.lungcan.2019.09.020 　

    詳細を見る 詳細を閉じる

    OBJECTIVES: Patients with concomitant advanced non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD) are excluded from most clinical chemotherapy trials because of the high risk of exacerbating the latter condition. This study prospectively investigated the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) in combination with carboplatin in patients with both advanced NSCLC and ILD. PATIENTS AND METHODS: The enrolled patients had treatment-naïve, advanced NSCLC with ILD. Patients received 100 mg/m2nab-paclitaxel weekly and carboplatin at an area under the concentration-time curve of 6 once every 3 weeks for 4-6 cycles. The primary endpoint was the overall response rate (ORR); secondary endpoints included toxicity, progression-free survival (PFS), and overall survival (OS). RESULTS: Thirty-six patients were enrolled between April 2014 and September 2017. Sixteen patients (44.4%) had adenocarcinoma, 15 (41.7%) had squamous cell carcinoma (Sq), and 5 (13.9%) had non-small cell carcinoma. The median number of cycles administered were 4 (range: 1-6). The ORR was 55.6% (95% confidence interval [CI]: 39.6-70.5). The median PFS and OS were 5.3 months (95% CI: 3.9-8.2) and 15.4 months (95% CI: 9.4-18.7), respectively. A greater proportion of patients with Sq experienced improvements than did those with non-Sq: ORRs, 66.7% (95% CI: 41.7-84.8) vs. 47.6% (95% CI: 28.3-67.6) (P = 0.254); median PFS, 8.2 months (95% CI: 4.0-10.2) vs. 4.1 months (95% CI: 3.3-5.4) (HR, 0.60 [95% CI, 0.30-1.20]; P = 0.15); and median OS, 16.8 months (95% CI: 9.8-not reached) vs. 11.9 months (95% CI: 7.3-17.4) (HR, 0.56 [95% CI, 0.24-1.28]; P = 0.17). Two patients (5.6%) experienced grade ≥2 pneumonitis and 1 patient (2.8%) died. CONCLUSION: Weekly nab-paclitaxel combined with carboplatin showed favorable efficacy with acceptable toxicity in patients with both advanced NSCLC and ILD.

  47. 間質性肺炎合併進行非小細胞肺癌に対するカルボプラチン+ナブパクリタキセル併用療法の第II相試験

    高村 圭, 朝比奈 肇, 大泉 聡史, 原田 敏之, 原田 眞雄, 横内 浩, 金沢 賢也, 藤田 結花, 小島 哲弥, 菅谷 文子, 田中 寿志, 本田 亮一, 猪狩 智生, 荻 喬博, 清水 薫子, 鈴木 雅, 今野 哲, 秋田 弘俊, 磯部 宏, 西村 正治, 北海道肺癌臨床研究会

    肺癌　59　(6)　687-687　2019年11月

    出版者・発行元： (NPO)日本肺癌学会

    ISSN：0386-9628

    eISSN：1348-9992

  48. 当科におけるデュルバルマブ使用症例の後方視的検討

    辻 康介, 水柿 秀紀, 猪狩 智生, 佐藤 峰嘉, 國崎 守, 高島 雄太, 古田 恵, 朝比奈 肇, 菊地 順子, 菊地 英毅, 榊原 純, 品川 尚文, 今野 哲

    肺癌　59　(6)　776-776　2019年11月

    出版者・発行元： (NPO)日本肺癌学会

    ISSN：0386-9628

    eISSN：1348-9992

  49. 気管支鏡検査におけるFFPE組織検体および細胞検体を用いたROS1融合遺伝子の検査成功率の検証

    辻 康介, 榊原 純, 北井 秀典, 猪狩 智生, 佐藤 峰嘉, 高橋 宏典, 國崎 守, 庄司 哲明, 高島 雄太, 古田 恵, 水柿 秀紀, 朝比奈 肇, 菊地 順子, 菊地 英毅, 品川 尚文, 樋田 泰浩, 加賀 基知三, 大井 優子, 中條 聖子, 畑中 佳奈子, 畑中 豊, 松野 吉宏, 今野 哲

    気管支学　41　(6)　678-678　2019年11月

    出版者・発行元： (NPO)日本呼吸器内視鏡学会

    ISSN：0287-2137

    eISSN：2186-0149

  50. 当科におけるクライオバイオプシーの使用経験

    國崎 守, 品川 尚文, 辻 康介, 佐藤 理子, 猪狩 智生, 佐藤 峰嘉, 高橋 宏典, 高島 雄太, 古田 恵, 庄司 哲明, 水柿 秀紀, 朝比奈 肇, 菊地 英毅, 菊地 順子, 榊原 純, 今野 哲, 松野 吉宏

    気管支学　41　(6)　678-678　2019年11月

    出版者・発行元： (NPO)日本呼吸器内視鏡学会

    ISSN：0287-2137

    eISSN：2186-0149

  51. 当科における非小細胞肺癌化学放射線療法後のデュルバルマブ使用症例の後方視的検討

    辻 康介, 水柿 秀紀, 猪狩 智生, 佐藤 峰嘉, 國崎 守, 北井 秀典, 朝比奈 肇, 菊地 順子, 菊地 英毅, 榊原 純, 品川 尚文

    日本サルコイドーシス/肉芽腫性疾患学会雑誌　39　(1-2)　116-116　2019年10月

    出版者・発行元： 日本サルコイドーシス

    ISSN：1883-1273

  52. Response to First-Line Osimertinib Treatment in Non-Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations. 国際誌

    Tomoo Ikari, Jun Sakakibara-Konishi, Gaku Yamamoto, Hidenori Kitai, Hidenori Mizugaki, Hajime Asahina, Eiki Kikuchi, Naofumi Shinagawa

    Clinical lung cancer　20　(4)　e531-e533　2019年7月

    DOI： 10.1016/j.cllc.2019.05.002 　

  53. 当院におけるBRAF遺伝子変異の検査成功率の検討

    山本 岳, 品川 尚文, 辻 康介, 猪狩 智生, 佐藤 峰嘉, 國崎 守, 高橋 宏典, 庄司 哲明, 高島 雄太, 古田 恵, 水柿 秀紀, 朝比奈 肇, 菊地 英毅, 菊地 順子, 木下 一郎, 秋田 弘俊, 畑中 豊, 松野 吉宏, 榊原 純

    気管支学　41　(Suppl.)　S221-S221　2019年6月

    出版者・発行元： (NPO)日本呼吸器内視鏡学会

    ISSN：0287-2137

    eISSN：2186-0149

  54. 気管支鏡検査におけるFFPE検体,細胞診検体を用いたROS1融合遺伝子の検査成功率の検証

    辻 康介, 榊原 純, 北井 秀典, 猪狩 智生, 佐藤 峰嘉, 高橋 宏典, 國崎 守, 庄司 哲明, 高島 雄太, 古田 恵, 水柿 秀紀, 朝比奈 肇, 菊地 順子, 菊地 英毅, 大井 優子, 中條 聖子, 畑中 佳奈子, 畑中 豊, 松野 吉宏, 品川 尚文

    気管支学　41　(Suppl.)　S222-S222　2019年6月

    出版者・発行元： (NPO)日本呼吸器内視鏡学会

    ISSN：0287-2137

    eISSN：2186-0149

  55. 当科におけるクライオバイオプシーの使用経験

    國崎 守, 品川 尚文, 山本 岳, 辻 康介, 瀧本 理子, 猪狩 智生, 佐藤 峰嘉, 高橋 宏典, 高島 雄太, 古田 恵, 庄司 哲明, 水柿 秀紀, 朝比奈 肇, 菊地 英毅, 菊地 順子, 榊原 純

    気管支学　41　(Suppl.)　S351-S351　2019年6月

    出版者・発行元： (NPO)日本呼吸器内視鏡学会

    ISSN：0287-2137

    eISSN：2186-0149

  56. Response of BRAFV600E-Mutant Lung Adenocarcinoma With Brain Metastasis and Leptomeningeal Dissemination to Dabrafenib Plus Trametinib Treatment. 国際誌

    Gaku Yamamoto, Jun Sakakibara-Konishi, Tomoo Ikari, Hidenori Kitai, Hidenori Mizugaki, Hajime Asahina, Eiki Kikuchi, Naofumi Shinagawa

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer　14　(5)　e97-e99　2019年5月

    DOI： 10.1016/j.jtho.2018.12.027 　

  57. T790M検索を目的とした組織再生検及び血漿検査の後方視的検討

    猪狩 智生, 北井 秀典, 高橋 宏典, 國崎 守, 庄司 哲明, 古田 恵, 高島 雄太, 佐々木 真知子, 水柿 秀紀, 朝比奈 肇, 菊地 英毅, 菊地 順子, 榊原 純, 畑中 豊, 松野 吉宏, 品川 尚文

    肺癌　58　(6)　635-635　2018年10月

    出版者・発行元： (NPO)日本肺癌学会

    ISSN：0386-9628

    eISSN：1348-9992

  58. 致死的喀血に対しEndobronchial Watanabe Spigot(EWS)を用いた気管支充填術による一時的止血の後に根治的左肺全摘出術を施行し救命し得た一例

    猪狩 智生, 佐藤 未来, 竹藪 公洋, 飛岡 弘敏, 石川 慶大

    日本サルコイドーシス/肉芽腫性疾患学会雑誌　38　(1-2)　101-102　2018年10月

    出版者・発行元： 日本サルコイドーシス

    ISSN：1883-1273

  59. 喀血を来した続発性気管支動脈蔓状血管腫に対し気管支動脈塞栓術が奏功した一例

    佐藤 未来, 猪狩 智生, 高岡 和夫, 竹藪 公洋

    気管支学　40　(Suppl.)　S272-S272　2018年5月

    出版者・発行元： (NPO)日本呼吸器内視鏡学会

    ISSN：0287-2137

    eISSN：2186-0149

  60. 造影剤ショックを呈し気管支動脈塞栓術が不能であった特発性気道出血に対して外科的切除を施行した治療経験

    石川 慶大, 川村 健, 横山 和之, 進藤 学, 猪狩 智生, 佐藤 未来, 竹藪 公洋, 高岡 和夫, 飛岡 弘敏

    気管支学　40　(Suppl.)　S349-S349　2018年5月

    出版者・発行元： (NPO)日本呼吸器内視鏡学会

    ISSN：0287-2137

    eISSN：2186-0149

  61. カルボプラチン+nabパクリタキセル併用術前化学療法により完全切除可能となった肺多型癌の1例

    竹藪 公洋, 猪狩 智生, 佐藤 未来, 高岡 和夫, 石川 慶大, 川村 健, 飛岡 弘敏

    日本呼吸器学会誌　7　(増刊)　283-283　2018年3月

    出版者・発行元： (一社)日本呼吸器学会

    ISSN：2186-5876

    eISSN：2186-5884

  62. 胸壁腫瘍に対してGORE-TEX Dual Meshを用いた胸壁再建の手術経験

    石川 慶大, 竹藪 公洋, 川村 健, 進藤 学, 横山 和之, 佐藤 未来, 猪狩 智生, 高岡 和夫, 飛岡 弘敏

    肺癌　57　(5)　584-584　2017年9月

    出版者・発行元： (NPO)日本肺癌学会

    ISSN：0386-9628

    eISSN：1348-9992

  63. 右上葉肺癌・肋骨転移を伴う両側気胸に対して二期的手術を施行した1例

    石川 慶大, 川村 健, 横山 和之, 進藤 学, 竹藪 公洋, 佐藤 未来, 猪狩 智生, 高岡 和夫, 飛岡 弘敏

    日本気胸・嚢胞性肺疾患学会雑誌　17　(2)　106-106　2017年8月

    出版者・発行元： 日本気胸・嚢胞性肺疾患学会

    ISSN：1883-0412

  64. 肺癌の高度催吐性化学療法(HEC)時の悪心・嘔吐(CINV)予防に対する六君子湯の有用性に関する検討(HOT1402)

    猪狩 智生, 原田 敏之, 天野 虎次, 藤田 結花, 田中 寿志, 佐々木 高明, 高村 圭, 菅原 俊一, 秋田 弘俊, 磯部 宏, 西村 正治

    Palliative Care Research　12　(Suppl.)　S332-S332　2017年6月

    出版者・発行元： (NPO)日本緩和医療学会

    eISSN：1880-5302

  65. 右手中指末端皮膚転移をきたした肺腺癌の1例

    猪狩 智生, 中村 順一, 河井 康孝, 松前 元

    王子総合病院医学雑誌　(7)　59-62　2017年6月

    出版者・発行元： (医)王子総合病院

  66. 右手中指末端へ転移をきたした非小細胞肺癌の1例

    猪狩 智生, 高木 統一郎, 中村 順一, 河井 康孝, 松前 元, 鈴木 昭, 吉田 貴之

    肺癌　57　(1)　50-50　2017年2月

    出版者・発行元： (NPO)日本肺癌学会

    ISSN：0386-9628

    eISSN：1348-9992

  67. Multiple cavities with halo sign in a case of invasive pulmonary aspergillosis during therapy for drug-induced hypersensitivity syndrome. 国際誌

    Tomoo Ikari, Katsura Nagai, Masashi Ohe, Toshiyuki Harada, Yasushi Akiyama

    Respiratory medicine case reports　21　124-128　2017年

    DOI： 10.1016/j.rmcr.2017.04.017 　

    詳細を見る 詳細を閉じる

    A 67-year-old female with rheumatoid arthritis and asthma-chronic obstructive pulmonary disease overlap syndrome was admitted for drug-induced hypersensitivity syndrome (DIHS) caused by salazosulfapyridine. Human herpes virus 6 (HHV-6) variant B was strongly positive on peripheral blood. Multiple cavities with ground grass opacities rapidly emerged predominantly in the upper and middle lobes. She was diagnosed with invasive pulmonary aspergillosis (IPA), and was treated successfully with antifungal agents. Therapeutic systemic corticosteroids, emphysematous change in the lungs, and the worsening of the patient's general condition due to DIHS were considered major contributing factor leading to IPA. HHV-6 reactivation could have an effect on clinical course of IPA. Cavities with halo sign would provide an early clue to IPA in non-neutropenic and immunosuppressive patients.

  68. Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials. 国際誌

    Toshiyuki Harada, Toraji Amano, Tomoo Ikari, Kei Takamura, Takahiro Ogi, Toshiaki Fujikane, Yuka Fujita, Kageaki Taima, Hisashi Tanaka, Takaaki Sasaki, Shunsuke Okumura, Shunichi Sugawara, Hiroshi Yokouchi, Noriyuki Yamada, Naoto Morikawa, Hirotoshi Dosaka-Akita, Hiroshi Isobe, Masaharu Nishimura

    Frontiers in pharmacology　8　972-972　2017年

    DOI： 10.3389/fphar.2017.00972 　

    詳細を見る 詳細を閉じる

    The herbal medicine rikkunshito has the potential to improve chemotherapy-induced nausea and vomiting (CINV) by stimulating ghrelin secretion. We aimed to evaluate the efficacy and safety of rikkunshito in preventing CINV for patients with lung cancer. Two separate prospective, randomized, phase II parallel design studies were conducted in patients with lung cancer. Fifty-eight and sixty-two patients scheduled to receive highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC), respectively, were randomized 1:1 to receive either standard antiemetic therapy in accordance with international guidelines (S group) or standard antiemetic therapy plus oral rikkunshito (R group). The primary endpoint was overall complete response (CR)-that is, no emesis and rescue medication in the first 120 h post-chemotherapy. Secondary endpoints included CR in the acute (0-24 h) and delayed (>24-120 h) phases and safety. Fifty-seven patients (S group, 28; R group, 29) receiving HEC and sixty-two patients (S group, 30; R group, 32) receiving MEC with comparable characteristics were evaluated. The CR rates were similar across the S and R groups for the HEC study in the overall (67.9% vs. 62.1%), acute (96.4% vs. 89.6%), and delayed (67.9% vs. 62.1%) phases, respectively, and for the MEC study in the overall (83.3% vs. 84.4%), acute (100% vs. 100%), and delayed (83.3% vs. 84.4%) phases, respectively. No severe adverse events were observed. Although rikkunshito was well tolerated, it did not demonstrate an additional preventative effect against CINV in lung cancer patients receiving HEC or MEC. Clinical Trial Registry Information: This study is registered with the University Hospital Medical Information Network (UMIN) Clinical Trial Registry, identification numbers UMIN 000014239 and UMIN 000014240.

  69. 肺原発悪性リンパ腫の1例

    原田 敏之, 猪狩 智生, 水島 亜玲, 長井 桂, 秋山 也寸史, 大江 真司, 吉田 弘喜, 服部 淳夫, 黒澤 光俊

    肺癌　55　(7)　1108-1108　2015年12月

    出版者・発行元： (NPO)日本肺癌学会

    ISSN：0386-9628

    eISSN：1348-9992

︎全件表示 ︎最初の5件までを表示

MISC 8

  1. 訪問看護師のアンケート調査による、緩和ケアの専門家が不在の地域における緩和ケアアウトリーチの有効性

    佐藤 麻美子, 田上 恵太, 猪狩 智生, 佐竹 宣明, 田上 佑輔, 井上 彰

    Palliative Care Research　16　(Suppl.)　S435-S435　2021年6月

    出版者・発行元： (NPO)日本緩和医療学会

    eISSN： 1880-5302

  2. 【オピオイド鎮痛薬 適正使用に必要な看護のポイント】(Part 2)オピオイド鎮痛薬の種類と使い分け

    猪狩 智生, 田上 恵太

    看護技術　66　(8)　795-802　2020年7月

    出版者・発行元： (株)メヂカルフレンド社

    ISSN： 0449-752X

  3. 当科におけるデュルバルマブ使用症例の後方視的検討

    辻 康介, 水柿 秀紀, 猪狩 智生, 佐藤 峰嘉, 國崎 守, 高島 雄太, 古田 恵, 朝比奈 肇, 菊地 順子, 菊地 英毅, 榊原 純, 品川 尚文, 今野 哲

    肺癌　59　(6)　776-776　2019年11月

    出版者・発行元： (NPO)日本肺癌学会

    ISSN： 0386-9628

    eISSN： 1348-9992

  4. 気管支鏡検査におけるFFPE組織検体および細胞検体を用いたROS1融合遺伝子の検査成功率の検証

    辻 康介, 榊原 純, 北井 秀典, 猪狩 智生, 佐藤 峰嘉, 高橋 宏典, 國崎 守, 庄司 哲明, 高島 雄太, 古田 恵, 水柿 秀紀, 朝比奈 肇, 菊地 順子, 菊地 英毅, 品川 尚文, 樋田 泰浩, 加賀 基知三, 大井 優子, 中條 聖子, 畑中 佳奈子, 畑中 豊, 松野 吉宏, 今野 哲

    気管支学　41　(6)　678-678　2019年11月

    出版者・発行元： (NPO)日本呼吸器内視鏡学会

    ISSN： 0287-2137

    eISSN： 2186-0149

  5. 当科におけるクライオバイオプシーの使用経験

    國崎 守, 品川 尚文, 辻 康介, 佐藤 理子, 猪狩 智生, 佐藤 峰嘉, 高橋 宏典, 高島 雄太, 古田 恵, 庄司 哲明, 水柿 秀紀, 朝比奈 肇, 菊地 英毅, 菊地 順子, 榊原 純, 今野 哲, 松野 吉宏

    気管支学　41　(6)　678-678　2019年11月

    出版者・発行元： (NPO)日本呼吸器内視鏡学会

    ISSN： 0287-2137

    eISSN： 2186-0149

  6. 当院におけるBRAF遺伝子変異の検査成功率の検討

    山本 岳, 品川 尚文, 辻 康介, 猪狩 智生, 佐藤 峰嘉, 國崎 守, 高橋 宏典, 庄司 哲明, 高島 雄太, 古田 恵, 水柿 秀紀, 朝比奈 肇, 菊地 英毅, 菊地 順子, 木下 一郎, 秋田 弘俊, 畑中 豊, 松野 吉宏, 榊原 純

    気管支学　41　(Suppl.)　S221-S221　2019年6月1日

    出版者・発行元： (NPO)日本呼吸器内視鏡学会

    ISSN： 0287-2137

  7. 気管支鏡検査におけるFFPE検体,細胞診検体を用いたROS1融合遺伝子の検査成功率の検証

    辻 康介, 榊原 純, 北井 秀典, 猪狩 智生, 佐藤 峰嘉, 高橋 宏典, 國崎 守, 庄司 哲明, 高島 雄太, 古田 恵, 水柿 秀紀, 朝比奈 肇, 菊地 順子, 菊地 英毅, 大井 優子, 中條 聖子, 畑中 佳奈子, 畑中 豊, 松野 吉宏, 品川 尚文

    気管支学　41　(Suppl.)　S222-S222　2019年6月1日

    出版者・発行元： (NPO)日本呼吸器内視鏡学会

    ISSN： 0287-2137

  8. 当科におけるクライオバイオプシーの使用経験

    國崎 守, 品川 尚文, 山本 岳, 辻 康介, 瀧本 理子, 猪狩 智生, 佐藤 峰嘉, 高橋 宏典, 高島 雄太, 古田 恵, 庄司 哲明, 水柿 秀紀, 朝比奈 肇, 菊地 英毅, 菊地 順子, 榊原 純

    気管支学　41　(Suppl.)　S351-S351　2019年6月1日

    出版者・発行元： (NPO)日本呼吸器内視鏡学会

    ISSN： 0287-2137

︎全件表示 ︎最初の5件までを表示

書籍等出版物 2

  1. 東北大学病院緩和ケアbook : 緩和ケア専門外の医療者も知っておきたいエビデンス

    猪狩, 智生, 田上, 恵太, 井上, 彰

    中外医学社　2025年6月

    ISBN: 9784498057333

  2. 東北大学病院緩和ケアbook : 緩和ケア専門外の医療者も知っておきたいエビデンス

    猪狩, 智生, 田上, 恵太, 井上, 彰

    中外医学社　2022年4月

    ISBN: 9784498057326

講演・口頭発表等 1

  1. がん患者の死亡直前期予後予測におけるSurprise Questionの有用性に関する検討

    猪狩 智生

    2021年11月13日